Poster Presentations Session #1

WEDNESDAY APRIL 29th , 2026
2:00-3:30 PM
PGRL Gallery


Poster # Presenter Title of study/project
     
76 Dan Lu Functional modulation of p53 via combinatorial modifications.
55 Philipp Münick Designed Ankyrin Repeat Proteins as a novel tool to reactivate p53 in cancer.
3 Alvin Guo p53 regulates intracellular iron levels and enhances phagocytic clearance of bacteria and tumor cells in macrophages.
19 David Hoyos TP53 free fitness relates to LINE-1 activity and immune surveillance in Li-Fraumeni Syndrome tumors.
40 Magdalena Oroń Mutant p53 shapes an alternative splicing landscape in cancer - research into the mechanism and therapeutic possibilities.
53 Paulina Rios Understanding how the proteostasis network shapes the mutational landscape of TP53 in cancer.
21 Dominika Pieńkowska Activating p53Y220C with a Mutant-Specific Small Molecule.
23 Giulia Pantella p53, citrullination and ELF2 in the control of promoter selectivity.
31 Justin Heftel Targeted Delivery of DARPins via LNPs for Treatment of p53 Related Cancers.
32 Kai Ren Chen Predicting the age-of-onset for paediatric cancer in children with germline variants of TP53 regulators and wild-type TP53.
42 Maj-Britt Paulsohn Beyond p53: MDM2 Functions at CpG Islands to Modulate Chromatin and Transcription.
43 Manuel Contreras Elucidating Mechanisms of TP53-mediated Leukemia Immune Escape.
54 Pavitra Kannan A stapled peptide inhibitor of MDM2 enables pharmacological activation of p53 in zebrafish.
35 Kha The Nguyen Inhibition of the epitranscriptomic writer METTL3 is a therapeutic vulnerability specific for p53-deficient Pancreatic Ductal Adenocarcinomas.
47 Nabamita Boruah Distinct genomic remodeling in Li-Fraumeni Syndrome breast cancer.
2 Yan Zhu Nutlin-3a-mediated IL17RB repression leads to sustained p53 responses via modulating cellular level of p21 and Bcl-2.
5 Andrea Valdespino Elucidating the role of PADI4 in p53-mediated tumor suppression.
6 Anna Tymofyeyeva Ras–MAPK pathway convergence defines early therapeutic vulnerability in p53-deficient pediatric high-grade glioma.
44 Anna Puzio-Kuter Advancing Precision Medicine for TP53 Y220C–Mutant Cancers with Rezatapopt.
45 Megan Fisher Decoding p53(R249S)-mutated liver cancer: from developmental origin to targeted therapies.
8 Annemieke Bouwman Unraveling how distinct p53 hotspot mutations dictate immunotherapy response in breast cancer.
9 Annika Wylie Opposing transcriptional outcomes through the p53 isoform lens.
10 Ashby Kissoondoyal Early rhabdomyosarcoma priming in mice with germline TP53 mutations.
11 Barbara Łasut-Szyszka TP53 Role in Modulating Immune Surveillance in Early Breast Cancer.
13 Brianne Laverty Pediatric pan-cancer characterization of transposable elements and their modulation by germline TP53 variants.
46 Mitheera V Investigating the cooperation of p53 gene dosage and mutant Kras in driving non-small cell lung cancer.
48 Nabid Bhuiyan Decoding Functional Consequences of TP53 Mutations through Single-Cell RNA Sequencing.
57 Rebecca Jansche Non-canonical p53 functions in DNA replication and recombination as a novel tool for variant classification.
15 Camila Bolle Investigating the role of the p53 target gene Zmat3 in tumor suppression using in vivo and in vitro models of lung adenocarcinoma.
16 Camryn Neches In Search of a Stratified Toronto Protocol using Statistical Mechanics.
17 Danai Mavridi Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt.
18 Daria Dobrović Microenvironmental Control of mutp53-Driven Cell Competition.
22 Emma Kinloch Designer p53 as a tool to understand cell fate decisions.
49 Neda Slade Altered p53 Family Expression and Acquired Resistance to MAPK-Targeted Therapy in Melanoma.
50 Nicholas Fischer T cell over-activation and impaired effector function in Trp53-R172H mice.
58 Reet Bhandari Dissecting the roles of two different mutant P53 proteins in the development and sustained growth of tumours using novel genetically-engineered mouse models.
66 Suyin Pan (Tom Syme presenting on his behalf) Optimization of small molecule ligand of p53-Y220C.
86 Hailey Shankle Modifications of the p53 DNA Binding Domain Regulate Sequence Specificity.

👉 POSTER SESSION #2
THURSDAY APRIL 30th , 2026
2:00 – 3:30

 

/ program / poster-session-1